New Gene Inhibitor Drug for Patients with MTAP-Deleted Tumors
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
Precision medicine is no longer limited to targeted drug therapy; it has also been adopted in radiation therapy. In the past, radiation beams only matched the height and width of the tumor causing significant damage to the surround tissue. Advances in imaging technology have made it possible to locate and treat the tumor more precisely,…
Researchers are looking at a combination of two types of monoclonal antibodies to treat advanced pancreatic cancer.
Researchers are testing a thyroid drug to see if it is effective against pancreatic neuroendocrine tumors, among other cancers.
Researchers are testing a drug combination for melanoma in pancreatic cancer patients with a BRAF genetic mutation.
Researchers are conducting a phase 0 study of a new drug that may cause inflammation to stimulate immune system against cancer.
A platform clinical trial evaluates immunotherapy combinations with standard of care treatment for advanced pancreatic cancer.
A clinical trial tests an investigational drug, immunotherapy, and radiation in combination against advanced pancreatic cancer.
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
CRISPR technology is used as part of an immunotherapy clinical trial for metastatic pancreatic cancer and other GI cancers.